INDUSTRY WATCH: September/October 2014
QS/1 Enhances Billing Functionality
QS/1 is now offering Veridikal intelligence and Veridikal’s reconciliation program to reduce billing errors. Included are pre- and post-editing, EDI support, X12N 835 processing, forensic auditing, and reconciliation.
“The pre- and post-editing service evaluates prescription claims for omissions, errors, and compliance with industry standards and metrics,” says Revonda Spratt, VP of operations for QS/1. “This prevents the pharmacy from submitting a claim that would be rejected due to missing or inaccurate information and decreases the possibility of paying multiple submission charges on a single prescription.”
QS/1 also announced that it has added additional security measures to better validate electronic prescriptions for controlled substances (EPCS). Through its partnership with Surescripts, QS/1 pharmacy users already have access to the signature indicator, which is the most common signing approach by early adopters of EPCS.
But as John Frady, the company’s market analyst for pharmacy products, explains, “As more doctors use electronic means to prescribe controlled substances, there will be an increase in the use of the even more secure Federal Bridge Certificate Authority Public Key Infrastructure (FBCA PKI) standard.”
Frady further notes that while other pharmacy management system providers may have taken an easier route for EPCS security, QS/1 took the extra steps to use the FBCA PKI standard so that when this becomes the preferred method of validation, QS/1 will not have to go through the process of recertification.